X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on X4 Pharmaceuticals to $5 from $3.50 and keeps a Buy rating on the shares. The company announced positive top-line data from the Phase 3 randomized, placebo-controlled, 4WHIM study, Ramakanth tells investors in a research note. The anlayst is encouraged by the positive top-line data and increased the launch probability of mavorixafor as a treatment for WHIM syndrome to 60% from 48.5%.